An expanded understanding of the biology of breast cancer has led to the identification of the HER-2 receptor as an important growth factor. This receptor possesses intrinsic tyrosine kinase activity and has been associated with aggressive biological behavior and poor clinical outcome.
Methods:
Data have been reviewed regarding the role of HER-2 expression as a prognostic variable, as a predictive factor for response to chemotherapy and hormonal therapies, and as a directed therapeutic target for breast cancer.
Results:
Therapy with a humanized monoclonal antibody to HER-2 (trastuzumab) can be effective treatment in some patients with metastatic breast cancer, either given alone or in combination with some chemotherapeutic agents. Cardiac toxicity limits concurrent use with anthracyclines. Clinical trials will further define optimal combination regimens with this agent, and its value in patients with localized or locally advanced stages.
Conclusions:
Trastuzumab is a significant addition to the armamentarium against breast cancer. Standardization of the optimal method to evaluate for HER-2 overexpression is necessary to better define its role as a prognostic, predictor, and therapeutic target in this disease.
References
1.
HynesN.E., SternD.F.. The biology of erbB-2/neu/HER-2 and its role in cancer.Biochim Biophys Acta.1994; 1198: 165–184.
2.
KrausM.H., IssingW., MikiT.. Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors.Proc Natl Acad Sci U S A.1989; 86: 9193–9197.
3.
PlowmanG.D., CulouscouJ.M., WhitneyG.S.. Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family.Proc Natl Acad Sci U S A.1993; 90: 1746–1759.
4.
ShihC., PadhyL.C., MurrayM.. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts.Nature.1981; 290: 261–264.
5.
SundaresanS., RobertsP.E., KingK.L.. Biological response to ErbB ligands in nontransformed cell lines correlates with a specific pattern of receptor expression.Endocrinology.1998; 139: 4756–4764.
6.
TanM., YaoJ., YuD.. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities.Cancer Res.1997; 57: 1199–1205.
7.
AdamL., VadlamudiR., KondapakaS.. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinostol-3 kinase.J Biol Chem.1998; 273: 28238–28246.
8.
ChenL., ZhangW., FregienN.. The Her-2/neu oncogene stimulates the transcription of N-acetylglucosaminyltransferase V and expression of its cell surface oligosaccharide products.Oncogene.1998; 17: 2087–2093.
9.
PegramM.D., FinnR.S., ArzooK.. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cells.Oncogene.1997; 15: 537–547.
10.
GebhardtF., ZänkerK., BrandtB.. Differential expression of alternatively spliced c-erbB-2 mRNA in primary tumors, lymph node metastases, and bone marrow micro metastases from breast cancer patients.Biochem Biophys Res Commun.1998; 247: 319–323.
11.
HancockM.C., LangtonB.C., ChanT.. A monoclonal antibody against the C-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines.Cancer Res.1991; 51: 4575–4580.
12.
DrebinJ.A., LinkV.C., SternD.F.. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies.Cell.1985; 41: 697–706.
13.
StancovskiI., HurwitzE., LeitnerO.. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth.Proc Natl Acad Sci U S A.1991; 88: 8691–8695.
14.
HudziakR.M., LewisG.D., WingetM.. p185HER2 monoclonal antibody has antiproliferative effect in vitro and sensitizes human breast tumor cells to tumor necrosis factor.Mol Cell Biol.1989; 9: 1165–1172.
15.
CarterP., PrestaL., GormanC.M.. Humanization of an anti-p185HER2 antibody for human cancer therapy.Proc Natl Acad Sci U S A.1992; 89: 4285–4289.
16.
Herceptin package insert.Genentech Inc, South San Francisco, Calif.1998.
17.
SlamonD.J., ClarkG.M., WongS.G.. Human breast cancer: correlation of relapse and survival with amplification of the Her-2/neu oncogene.Science.1997; 235: 177–182.
18.
BergerM.S., LocherG.W., SaurerS.. Correlation of c-erbB-2 gene amplification and protein expression of human breast carcinoma with nodal status and nuclear grading.Cancer Res.1988; 48: 1238–1243.
19.
PressM.F., PikeM.C., ChazinV.R.. Her-2/neu expression in node-negative breast cancer: Direct tissue quantitation by computerized image analysis and association with overexpression with increased risk of recurrent disease.Cancer Res.1993; 53: 4960–4970.
20.
PressM.F., BernsteinL., ThomasP.A.. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.J Clin Oncol.1997; 15: 2894–2904.
21.
ClarkG.M.. Should selection of adjuvant chemotherapy for patients with breast cancer be based on erbB-2 status?J Natl Cancer Inst.1998; 90: 1320–1321.
22.
ThorA.D., BerryD.A., BudmanD.R.. erbB-2, p53, and the efficacy of adjuvant therapy in lymph node positive breast cancer.J Natl Cancer Inst.1998; 90: 1346–1360.
23.
PaikS., BryantJ., ParkC.. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive hormone receptor-negative breast cancer.J Natl Cancer Inst.1998; 90: 1361–1370.
24.
BiancoA.R., DeLaurentiisM., CarlomagnoC.. 20 year update of the Naples GUN trial of adjuvant breast cancer therapy: evidence of interaction between c-erb-B2 expression and tamoxifen efficacy.Proc Annu Meet Am Soc Clin Oncol.1998; 17: 97a. Abstract.
25.
YamauchiH., O'NeillA., GelmanR.. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels or extracellular domain of the Her-2/c-neu protein.J Clin Oncol.1997; 15: 2518–2525.
26.
ElledgeR.M., GreenS., CioccaD.. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.Clin Cancer Res.1998; 4: 7–12.
27.
ArcherC.D., EllisP.A., DowsettM.. C-erbB-2 positivity in primary correlates with poor apoptosis response to chemotherapy in primary breast cancer.Breast Cancer Res Treat.1998; 50: 237. Abstract.
28.
PlunkettT.A., HoustonS.J., RubensR.D.. Her-2 overexpression is a marker of resistance to endocrine therapy in advanced breast cancer.Breast Cancer Res Treat.1998; 50: 238. Abstract.
29.
StenderM.J., NeubergD., WoodN.. Correlation of circulating c-erb B-2 extracellular domain (Her-2) with clinical outcome in patients with metastatic breast cancer.Proc Annu Meet Am Soc Clin Oncol.1998; 16: 154a. Abstract.
30.
ColomerR., MonteroS., LluchA.. Circulating Her-2/neu predicts resistance to Taxol/Adriamycin in metastatic breast carcinoma: preliminary results of a multicentric prospective study.Proc Annu Meet Am Soc Clin Oncol.1998; 16: 140a. Abstract.
31.
CobleighM.A., VogelC.L., TripathyN.J.. Efficacy and safety of Herceptin (humanized anti-Her-2 antibody) as a single agent in 222 women with Her-2 overexpression who relapsed following chemotherapy for metastatic breast cancer.Proc Annu Meet Am Soc Clin Oncol.1998; 17: 97a. Abstract.
32.
SlamonD., Leyland-JonesB., ShakS.. Addition of Herceptin (humanized anti-Her-2 antibody) to first-line chemotherapy for Her-2 overexpressing metastatic breast cancer (Her-2 ± MBC) markedly increases anticancer activity: a randomized multinational controlled phase III trial.Proc Annu Meet Am Soc Clin Oncol.1998; 17: 98a. Abstract.
BaselgaJ., NortonL., AlbanellJ.. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.Cancer Res.1998; 58: 2825–2831.
37.
HancockM.C., LangtonB.C., ChanT.. A monoclonal antibody against the C-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines.Cancer Res.1991; 51: 4575–4580.
38.
ArteagaC.L., WinnierA.R., PoirierM.C.. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair.Cancer Res.1994; 54(14): 3758–3765.
39.
PietrasR.J., FendlyB.M., ChazinV.R.. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.Oncogene.1994; 9: 1829–1838.
40.
PietrasR.J., PegramM.D., FinnR.S.. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.Oncogene.1998; 17: 2235–2249.
41.
BaselgaJ., TripathyD., MendelsohnJ.. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.J Clin Oncol.1996; 14: 737–744.
42.
PegramM.D., LiptonA., HayesD.F.. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185-HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.J Clin Oncol.1998; 16: 2659–71.
43.
VogelC.L., CobleighM.A., TripathyD.. Efficacy and Safety of Herceptin (trastuzumab, humanized anti-Her2 antibody) as a single agent in first-line treatment of Her2 overexpressing metastatic breast cancer (Her2+/MBC).Breast Cancer Res Treat.1998; 50: 232. Abstract.
44.
HudisC., SeidmanA., PatonV.. Characterization of cardiac dysfunction observed in the Herceptin (trastuzumab) clinical trials.Breast Cancer Res Treat.1998; 50: 232. Abstract.
